Epicrispr Advances Epigenetic Therapy With Promising FSHD Clinical Data
SAN FRANCISCO, Calif., June 26, 2026 Epicrispr Biotechnologies announced encouraging interim Phase 1/2 clinical trial results for EPI-321, its...
epigenetic therapy
Advertisement
BioMarin VOXZOGO Shows Long-Term Growth Benefits
San Rafael, California, United States | May 2, 2026 BioMarin Pharmaceutical Inc. has presented new long-term clinical data for...
Scribe Therapeutics Showcases CRISPR and STX-1150 Data
Alameda, California, United States | April 30, 2026 Scribe Therapeutics has announced significant advancements in its engineered CRISPR gene...
Adagene Reports Strong Muzastotug KEYTRUDA CRC Data
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
IDEAYA Biosciences Doses First Patient in IDE574 Trial
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
Advertisement
